Skip to content

Jazz Pharmaceuticals JAZZ Cash Provided by (Used in) Operating Activity, Including Discontinued Operation

Cash Provided by (Used in) Operating Activity, Including Discontinued Operation at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$792.82M-426%
Amgen logo
AmgenAMGN
Biogen logo
BiogenBIIB
Royalty Pharma logo
Royalty PharmaRPRX
ResMed logo
ResMedRMD
Summit Therapeutics logo
Summit TherapeuticsSMMT

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation?
Jazz Pharmaceuticals (JAZZ) reported cash provided by (used in) operating activity, including discontinued operation of $408.2M in Q1 2026.
How has Jazz Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation changed year-over-year?
Jazz Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation decreased by 5.0% year-over-year, from $429.8M to $408.2M.
What is the long-term trend for Jazz Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation?
Over 4 years (2021 to 2025), Jazz Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation has grown at a 14.9% compound annual growth rate (CAGR), from $778.51M to $1.36B.
What does cash provided by (used in) operating activity, including discontinued operation mean?
The net amount of cash the company generated from its day-to-day business activities.
How do you interpret cash provided by (used in) operating activity, including discontinued operation?
A positive value indicates the business is self-sustaining, while a negative value suggests reliance on external financing or asset sales.
How does cash provided by (used in) operating activity, including discontinued operation compare across companies?
The most critical metric for assessing financial health; peers in the same industry should demonstrate consistent positive cash flow relative to revenue.